CVS Health Corporation $CVS Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 26.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,810 shares of the pharmacy operator’s stock after buying an additional 6,647 shares during the quarter. GAMMA Investing LLC’s holdings in CVS Health were worth $3,291,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Norges Bank acquired a new stake in CVS Health during the 4th quarter worth $1,666,265,000. Wellington Management Group LLP boosted its stake in CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of CVS Health by 1,020.7% during the first quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock worth $347,984,000 after purchasing an additional 4,412,882 shares during the last quarter. Amundi grew its holdings in shares of CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of CVS Health by 44.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after purchasing an additional 1,899,932 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $99.24 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a fifty-two week low of $62.52 and a fifty-two week high of $110.68. The firm has a 50-day simple moving average of $102.10 and a 200-day simple moving average of $87.56. The company has a market capitalization of $126.62 billion, a price-to-earnings ratio of 43.72, a price-to-earnings-growth ratio of 1.02 and a beta of 0.61.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. During the same period in the prior year, the business earned $1.81 EPS. The firm’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities research analysts anticipate that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is 117.18%.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CVS shares. Bank of America upped their target price on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Weiss Ratings raised CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 20th. DA Davidson boosted their price objective on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. TD Cowen increased their price objective on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Wells Fargo & Company lifted their target price on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Twenty-one analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $105.67.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Strong quarterly beat: CVS reported adjusted EPS of $2.58, well above the roughly $1.86–$1.87 consensus, while revenue rose 7.3% year over year to $106.1 billion, exceeding estimates near $100 billion. All three major segments—insurance, pharmacy and health services—reportedly surpassed revenue expectations. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: Insurance turnaround is showing progress: Lower-than-expected medical costs and improved performance at Aetna helped drive the profit increase, while better-rated government health plans generated bonus payments. A more profitable pharmacy drug mix also supported results. CVS raises annual profit forecast on improved drug revenues
• Positive Sentiment: Guidance and cash flow increased: CVS raised 2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50 and lifted operating cash-flow guidance to at least $11.5 billion from $9.5 billion. CVS Health reports strong second quarter results and raises full-year guidance
• Positive Sentiment: GLP-1 opportunity expanded: A new collaboration with Eli Lilly will broaden CVS’s direct-to-consumer weight-management services and access to Zepbound and other GLP-1 medications, potentially creating additional pharmacy and care-service revenue. CVS enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: Despite the earnings beat, CVS’s valuation and recent rally may have raised investor expectations, making the market more sensitive to cautious commentary and execution risks.
• Negative Sentiment: Management remarks concerning the PBM unit reportedly prompted the initial gains to reverse. Investors may be concerned about Caremark’s competitive, pricing and margin outlook, limiting enthusiasm for the higher guidance. CVS Health reverses early gains after management remarks on PBM unit

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.